Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s): MEDXF

Healthcare

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

TSX:MDP - Post by User

Medexus Pharmaceuticals Inc

Bullboard Posts

Post by alwyslongtermon Jan 09, 2019 11:20am

80 Views

Post# 29206119

Fully Divested

Bought in the low thirties before the drop to $0.15 cents. Bought again at $0.22.

Sold it all - Don't believe this was an accretive acquisition.

I hope for the longs sake that this performs well going forward. Patience ran out after 4 years.

All the best.

Bullboard Posts

Morning Market Outlook for Nov. 14, 2024